clofibric acid has been researched along with gw 501516 in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Beneton, V; Boullay, AB; Boyer, T; Brewster, AG; Donche, F; Forest, MC; Fouchet, MH; Gellibert, FJ; Grillot, DA; Lambert, MH; Laroze, A; Le Grumelec, C; Linget, JM; Montana, VG; Nguyen, VL; Nicodème, E; Patel, V; Penfornis, A; Pianetti, PM; Pineau, O; Pohin, D; Potvain, F; Poulain, G; Ruault, CB; Saunders, M; Sierra, ML; Toum, J; Xu, HE; Xu, RX | 1 |
1 other study(ies) available for clofibric acid and gw 501516
Article | Year |
---|---|
Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.
Topics: Animals; Apolipoprotein A-I; Cholesterol, HDL; Cholesterol, VLDL; Crystallography, X-Ray; Dogs; Dyslipidemias; Humans; Ligands; Mice; Mice, Inbred C57BL; Mice, Transgenic; Models, Molecular; PPAR alpha; Propionates; Protein Structure, Tertiary; Rats; Rats, Wistar; Structure-Activity Relationship; Thiazoles; Triglycerides | 2007 |